Joan Herman - Ionis Pharmaceuticals Director
| IONS Stock | USD 43.09 0.08 0.19% |
Director
Ms. Joan Elizabeth Herman is Director of the Company. Ms. Herman is currently president and CEO of Herman Associates, a management consulting firm that specializes in advising private equity firms investing in healthcare. She has deep experience leading healthcare and payor companies, serving in several executive positions at Anthem, including as president and CEO of the Consumer Business unit, president and CEO of the Specialty, Senior and State Sponsored Business and group president, Senior and Specialty Businesses. Ms. Herman also served as a senior vice president of Phoenix Life Insurance Company since 2019.
| Age | 64 |
| Tenure | 5 years |
| Professional Marks | MBA |
| Address | 2855 Gazelle Court, Carlsbad, CA, United States, 92010 |
| Phone | 760 931 9200 |
| Web | https://www.ionispharma.com |
Ionis Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.0751) % which means that it has lost $0.0751 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7634) %, meaning that it created substantial loss on money invested by shareholders. Ionis Pharmaceuticals' management efficiency ratios could be used to measure how well Ionis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.13 in 2024. Return On Capital Employed is likely to drop to -0.15 in 2024. At this time, Ionis Pharmaceuticals' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 365.6 M in 2024, whereas Intangible Assets are likely to drop slightly above 24.2 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Jeffrey Johnson | Jaguar Animal Health | 45 | |
| Jean Belanger | Acasti Pharma | N/A | |
| John Micek | Jaguar Animal Health | 64 | |
| Adrian Montgomery | Acasti Pharma | N/A | |
| Kermit Anderson | Adial Pharmaceuticals | 67 | |
| Katherine Crewe | Acasti Pharma | N/A | |
| Gregory Divis | Jaguar Animal Health | 50 | |
| Kurt Graves | Pulmatrix | 47 | |
| David MacNaughtan | Jaguar Animal Health | 50 | |
| JeanClaude Debard | Acasti Pharma | N/A | |
| Gregory French | Pulmatrix | 53 | |
| Richard Conley | Pulmatrix | 63 | |
| Valier Boivin | Acasti Pharma | N/A | |
| JeanMarie Canan | Acasti Pharma | 57 | |
| Jonathan Siegel | Jaguar Animal Health | 44 | |
| Zhi Yang | Jaguar Animal Health | 61 | |
| Ari Azhir | Jaguar Animal Health | 69 | |
| Steven Gillis | Pulmatrix | 65 | |
| Donald Olds | Acasti Pharma | 57 | |
| Akihisa Akao | Pulmatrix | 59 | |
| Jiahao Qiu | Jaguar Animal Health | 31 | |
Management Performance
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.0751 |
Ionis Pharmaceuticals Leadership Team
Elected by the shareholders, the Ionis Pharmaceuticals' board of directors comprises two types of representatives: Ionis Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ionis. The board's role is to monitor Ionis Pharmaceuticals' management team and ensure that shareholders' interests are well served. Ionis Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ionis Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patrick Esq, Chief VP | ||
| Joseph Klein, Independent Director | ||
| Brett Monia, Sr. VP of Drug Discovery and Corporate Devel. | ||
| MA MBA, Executive CFO | ||
| Hayley Soffer, Vice Communications | ||
| Richard Geary, Executive Officer | ||
| Michael Hayden, Director | ||
| Spencer Berthelsen, Independent Director | ||
| Frederick Muto, Independent Director | ||
| Breaux Castleman, Independent Director | ||
| Onaiza CadoretManier, Chief VP | ||
| Peter Reikes, Director | ||
| Patrick ONeil, Senior Vice President - Legal, General Counsel | ||
| Ben Strain, IR Contact Officer | ||
| Lynne Parshall, COO, Corporate Secretary, Director | ||
| Joan Herman, Director | ||
| Dr BSc, Executive Officer | ||
| Joseph Loscalzo, Director | ||
| Eric Swayze, Ex Research | ||
| Joseph Wender, Independent Director | ||
| Wade Walke, Vice President - Corporate Communications | ||
| Sarah Boyce, Chief Business Officer | ||
| Frank Bennett, Senior Vice President - Antisense Research | ||
| JD Esq, Strategic Director | ||
| Damien McDevitt, Chief Business Officer | ||
| Joel Edwards, VP Operations | ||
| Stanley Crooke, Chairman of the Board and Presidentident, CEO | ||
| Elizabeth Hougen, CFO and Sr. VP of Fin. | ||
| Darren Gonzales, Chief VP |
Ionis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ionis Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.0751 | ||||
| Profit Margin | (0.47) % | ||||
| Operating Margin | 0.05 % | ||||
| Current Valuation | 5.9 B | ||||
| Shares Outstanding | 145.85 M | ||||
| Shares Owned By Insiders | 0.86 % | ||||
| Shares Owned By Institutions | 99.14 % | ||||
| Number Of Shares Shorted | 9.53 M | ||||
| Price To Earning | 101.16 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ionis Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Ionis Stock analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| CEOs Directory Screen CEOs from public companies around the world |
Is Ionis Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ionis Pharmaceuticals. If investors know Ionis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ionis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.44) | Earnings Share (2.56) | Revenue Per Share 5.501 | Quarterly Revenue Growth 1.136 | Return On Assets (0.08) |
The market value of Ionis Pharmaceuticals is measured differently than its book value, which is the value of Ionis that is recorded on the company's balance sheet. Investors also form their own opinion of Ionis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ionis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ionis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ionis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ionis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ionis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ionis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.